Search research articles
Contact Us
Filters
Showing results (141-150 of 156) with videos related to
Page
of 16
Sort By:
Journal of the National Cancer Institute
|
March 1, 1982
Phenotypic and genotypic characteristics of a cell line from a squamous cell carcinoma of human skin
P Boukamp, W Tilgen, R T Dzarlieva, et al.
Cancer Research
|
December 1, 1990
Expression of epithelial antigens Exo-1 and EPM-1 in human epidermal keratinocyte maturation and benign and malignant neoplasia
R Klingel, P Boukamp, R Moll, et al.
The Journal of Investigative Dermatology
|
May 8, 1999
Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor
U Reinhold, L Liu, H C Lüdtke-Handjery, et al.
Cancer
|
July 15, 1993
Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials
U Keilholz, C Scheibenbogen, W Tilgen, et al.
Cancer
|
April 15, 1992
Regional administration of lymphokine-activated killer cells can be superior to intravenous application
U Keilholz, P Schlag, W Tilgen, et al.
Leukemia
|
May 3, 2002
CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death
G Rappl, H Abken, J M Muche, et al.
Melanoma Research
|
June 1, 1995
Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG)
U R Kleeberg, E Engel, P Israels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 29, 2006
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study
D Schadendorf, A Hauschild, S Ugurel, et al.
British Journal of Cancer
|
April 20, 2001
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
A Hauschild, C Garbe, W Stolz, et al.
Acta Dermato-Venereologica
|
September 23, 1997
Ultraviolet light exposure, pigmentary traits and the development of melanocytic naevi and cutaneous melanoma. A case-control study of the German Central Malignant Melanoma Registry
M Breitbart, C Garbe, P Büttner, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 156) with videos related to
Sort By:
Page
of 16
Journal of the National Cancer Institute
|
March 1, 1982
Phenotypic and genotypic characteristics of a cell line from a squamous cell carcinoma of human skin
P Boukamp, W Tilgen, R T Dzarlieva, et al.
Cancer Research
|
December 1, 1990
Expression of epithelial antigens Exo-1 and EPM-1 in human epidermal keratinocyte maturation and benign and malignant neoplasia
R Klingel, P Boukamp, R Moll, et al.
The Journal of Investigative Dermatology
|
May 8, 1999
Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor
U Reinhold, L Liu, H C Lüdtke-Handjery, et al.
Cancer
|
July 15, 1993
Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials
U Keilholz, C Scheibenbogen, W Tilgen, et al.
Cancer
|
April 15, 1992
Regional administration of lymphokine-activated killer cells can be superior to intravenous application
U Keilholz, P Schlag, W Tilgen, et al.
Leukemia
|
May 3, 2002
CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death
G Rappl, H Abken, J M Muche, et al.
Melanoma Research
|
June 1, 1995
Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG)
U R Kleeberg, E Engel, P Israels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 29, 2006
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study
D Schadendorf, A Hauschild, S Ugurel, et al.
British Journal of Cancer
|
April 20, 2001
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
A Hauschild, C Garbe, W Stolz, et al.
Acta Dermato-Venereologica
|
September 23, 1997
Ultraviolet light exposure, pigmentary traits and the development of melanocytic naevi and cutaneous melanoma. A case-control study of the German Central Malignant Melanoma Registry
M Breitbart, C Garbe, P Büttner, et al.
Page
of 16